GI 301
Alternative Names: GI-301Latest Information Update: 28 Apr 2025
At a glance
- Originator GI Innovation
- Developer GI Innovation; Yuhan
- Class Allergens; Anti-inflammatories; Antiallergics; Antiasthmatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunoglobulin E inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Atopic dermatitis; Chronic urticaria; Food hypersensitivity
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Asthma in South Korea (Parenteral)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Atopic-dermatitis in South Korea (Parenteral)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Chronic-urticaria in South Korea (Parenteral)